Sarepta Therapeutics (NASDAQ:SRPT) Receives New Coverage from Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $165.00 price objective on the biotechnology company’s stock.

Several other analysts also recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Raymond James reissued an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. UBS Group upped their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Piper Sandler decreased their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $152.00 price target on shares of Sarepta Therapeutics in a report on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $182.95.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $132.02 on Monday. The business’s 50 day moving average price is $128.78 and its 200-day moving average price is $132.40. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The company has a market cap of $12.48 billion, a P/E ratio of 1,200.18 and a beta of 0.82. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same period in the previous year, the firm earned ($0.27) earnings per share. Sarepta Therapeutics’s quarterly revenue was up 38.9% compared to the same quarter last year. Sell-side analysts predict that Sarepta Therapeutics will post 1.45 earnings per share for the current year.

Insider Activity

In related news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Farallon Capital Management LLC increased its position in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Sarepta Therapeutics by 693.7% during the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after acquiring an additional 317,277 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in shares of Sarepta Therapeutics by 2,257.8% during the first quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock valued at $31,135,000 after acquiring an additional 230,300 shares in the last quarter. Rhumbline Advisers raised its position in shares of Sarepta Therapeutics by 146.3% in the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after purchasing an additional 160,942 shares during the last quarter. Finally, Blair William & Co. IL boosted its stake in Sarepta Therapeutics by 303.7% in the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock worth $27,537,000 after purchasing an additional 131,112 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.